WO1995025509A2 - Use of n-acyl derivatives of aminoalcohols in the manufacture of a medicament for practising neuroprotective action in neuropathological states connected with excitotoxicity - Google Patents

Use of n-acyl derivatives of aminoalcohols in the manufacture of a medicament for practising neuroprotective action in neuropathological states connected with excitotoxicity

Info

Publication number
WO1995025509A2
WO1995025509A2 PCT/EP1995/001002 EP9501002W WO9525509A2 WO 1995025509 A2 WO1995025509 A2 WO 1995025509A2 EP 9501002 W EP9501002 W EP 9501002W WO 9525509 A2 WO9525509 A2 WO 9525509A2
Authority
WO
WIPO (PCT)
Prior art keywords
use according
acid
group
pharmaceutical compositions
aromatic
Prior art date
Application number
PCT/EP1995/001002
Other languages
English (en)
French (fr)
Other versions
WO1995025509A3 (en
Inventor
Francesco Della Valle
Alberta Leon
Silvana Lorenzi
Original Assignee
Lifegroup S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lifegroup S.P.A. filed Critical Lifegroup S.P.A.
Priority to AU21090/95A priority Critical patent/AU2109095A/en
Priority to JP7524371A priority patent/JPH09510467A/ja
Priority to DE69510825T priority patent/DE69510825D1/de
Priority to US08/714,113 priority patent/US5925678A/en
Priority to CA002186243A priority patent/CA2186243C/en
Priority to EP95928865A priority patent/EP0804179B1/en
Publication of WO1995025509A2 publication Critical patent/WO1995025509A2/en
Publication of WO1995025509A3 publication Critical patent/WO1995025509A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Definitions

  • the present invention relates to the use of N-acyl derivatives of aminoalcohols with mono and dicarboxylic acids for the prevention and treatment of neuropathological states connected with excitotoxicity.
  • an aromatic carboxylic acid preferably benzoic acid.
  • chemical group X serves to increase the solubility in water and/or to modify the pharmacokinetic properties of the compound, giving a pro-drug.
  • the compounds according to the present invention are prepared by the different methods described hereinbelow.
  • N-(2-hydroxyethyl)-benzoylamide (1.65 g, 10 mmol), prepared according to Example 8 of the European patent application published with No. 0 550 006, was solubilized in anhydrous pyridine (15 nil) under stirring at 0°C and added with acetic anhydride (1.53 g). The resulting solution was stirred at 0°C for a period of 15 min and heated to 45°C for 24 hrs. The reaction mixture was evaporated to dryness in vacuo. The residue was taken up with water (30 ml) and extracted twice with ethyl acetate (20 ⁇ 2 ml).
  • the derivatives described herein can be advantageously used in the treatment of CNS disorders of humans and animals, whose etiology/evolution is associated with the hyper stimulation of excitatory amino acid receptors, in particular the NMDA receptor.
  • i) acute conditions hypooxia-ischaemia, stroke, brain and spinal cord injury, hypoglycaemia, cerebral hypoxic states associated with cardiovascular surgery
  • diseases inducing a prompt and massive Glu release such as epilepsy, transient ischaemic attacks (TIA), neurolathyrism
  • TIA transient ischaemic attacks
  • chronic degenerative diseases such as Hungtington's Chorea, Alzheimer's and Parkinson's diseases, amyotrophic lateral sclerosis and dementia, either primary or associated with other pathologies even of viral origin, such as acquired immunodeficiency syndrome (AIDS dementia complex).
  • AIDS dementia complex acquired immunodeficiency syndrome
  • Every capsule contains:
  • Every tube contains 5 g of product having the following composition: w/w
PCT/EP1995/001002 1994-03-21 1995-03-17 Use of n-acyl derivatives of aminoalcohols in the manufacture of a medicament for practising neuroprotective action in neuropathological states connected with excitotoxicity WO1995025509A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU21090/95A AU2109095A (en) 1994-03-21 1995-03-17 Use of n-acyl derivatives of aminoalcohols in the manufacture of a medicament for practising neuroprotective action in neuropathological states connected with excitotoxicity
JP7524371A JPH09510467A (ja) 1994-03-21 1995-03-17 興奮毒性に関連した神経病理学的な状態において神経保護作用を行う薬剤の製造におけるアミノアルコールのｎ−アシル誘導体の使用
DE69510825T DE69510825D1 (de) 1994-03-21 1995-03-17 Verwendung von n-acylderivaten aminoalcoholen zur herstellung eines medikamentes zum ausübung neuroprotektiver wirkung bei neuropathologischen mit excitotoxizität verbundenen zuständen
US08/714,113 US5925678A (en) 1994-03-21 1995-03-17 Use of N-acyl derivatives of aminoalcohols in the manufacture of a medicament for practicing neuroprotective action in neuropathological states connected with excitotoxicity
CA002186243A CA2186243C (en) 1994-03-21 1995-03-17 Use of n-acyl derivatives of aminoalcohols in the manufacture of a medicament for practising neuroprotective action in neuropathological states connected with excitotoxicity
EP95928865A EP0804179B1 (en) 1994-03-21 1995-03-17 Use of n-acyl derivatives of aminoalcohols in the manufacture of a medicament for practising neuroprotective action in neuropathological states connected with excitotoxicity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI940523A IT1271623B (it) 1994-03-21 1994-03-21 N-acilderivati di aminoalcoli con acidi monocarbossilici e bicarbossilici con attivita' neuroprotettiva nelle patologie neurologiche correlate ad eccitotossicita'
ITMI94A000523 1994-03-21

Publications (2)

Publication Number Publication Date
WO1995025509A2 true WO1995025509A2 (en) 1995-09-28
WO1995025509A3 WO1995025509A3 (en) 1995-10-12

Family

ID=11368280

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1995/001002 WO1995025509A2 (en) 1994-03-21 1995-03-17 Use of n-acyl derivatives of aminoalcohols in the manufacture of a medicament for practising neuroprotective action in neuropathological states connected with excitotoxicity

Country Status (8)

Country Link
US (1) US5925678A (und)
EP (1) EP0804179B1 (und)
JP (1) JPH09510467A (und)
AT (1) ATE182075T1 (und)
AU (1) AU2109095A (und)
DE (1) DE69510825D1 (und)
IT (1) IT1271623B (und)
WO (1) WO1995025509A2 (und)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996018391A2 (en) * 1994-12-14 1996-06-20 Lifegroup S.P.A. Use of mono and bicarboxylic acid amides for the manufacture of a medicament active at the peripheral cannabinoid receptor
WO2002094302A1 (en) * 2001-05-23 2002-11-28 Gil-Ja Jhon Compositions comprising extract of ganoderma lucidum, oleamide and its structural analogue as an effective component for preventing or treating dementia

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410597B1 (en) * 2000-02-25 2002-06-25 Virginia Commonwealth University Hydroxyalkyl amide analogs of ceramide
WO2004096256A1 (en) * 2001-01-23 2004-11-11 The United States Of America, As Represented By The Secretary Of The Navy Methods for preventing and treating loss of balance function due to oxidative stress
ITMI20011483A1 (it) * 2001-07-11 2003-01-11 Res & Innovation Soc Coop A R Uso di composti come antagonisti funzionali ai recettori centrali deicannabinoidi
DE10351111A1 (de) * 2003-11-03 2005-06-16 Langlotz, Rainer Arzneimittel und Verfahren zu ihrer Herstellung
AU2017341769B2 (en) * 2016-10-13 2021-11-11 Carnot, Llc N-Acylethanolamide derivatives and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0177245A2 (en) * 1984-09-28 1986-04-09 Nippon Chemiphar Co., Ltd. Amino-alcohol derivatives and processes for their preparation
EP0550008A2 (en) * 1991-12-31 1993-07-07 LIFEGROUP S.p.A. Use of N-acyl derivatives of aminoalcohols with polycarboxylic acids for the manufacture of a medicament for the treatment of pathologies relating to mast cells
US5227397A (en) * 1989-04-28 1993-07-13 Pfizer Inc. Polyamines and polypeptides useful as antagonists of excitatory amino acid neuro-transmitters and/or as blockers of calcium channels
EP0570714A2 (en) * 1992-04-24 1993-11-24 LIFEGROUP S.p.A. Aminoalcohols-n-acylderivatives as therapeutical agents against the neurogenic endoneural oedema developing at the peripheral nerve
WO1993025203A1 (en) * 1992-06-17 1993-12-23 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method of treating and protecting against central nervous system ischemia, hypoxia, degeneration, and trauma with a 5-aminocarbonyl-sh-dibenzo[a,d]cyclohepten-5,10-imine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618842A (en) * 1991-12-31 1997-04-08 Lifegroup S.P.A. N-acyl derivatives of aminoalcohols with polycarboxylic acids able to modulate mast cells in inflammatory processes having neuroimmunogenic origin

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0177245A2 (en) * 1984-09-28 1986-04-09 Nippon Chemiphar Co., Ltd. Amino-alcohol derivatives and processes for their preparation
US5227397A (en) * 1989-04-28 1993-07-13 Pfizer Inc. Polyamines and polypeptides useful as antagonists of excitatory amino acid neuro-transmitters and/or as blockers of calcium channels
EP0550008A2 (en) * 1991-12-31 1993-07-07 LIFEGROUP S.p.A. Use of N-acyl derivatives of aminoalcohols with polycarboxylic acids for the manufacture of a medicament for the treatment of pathologies relating to mast cells
EP0570714A2 (en) * 1992-04-24 1993-11-24 LIFEGROUP S.p.A. Aminoalcohols-n-acylderivatives as therapeutical agents against the neurogenic endoneural oedema developing at the peripheral nerve
WO1993025203A1 (en) * 1992-06-17 1993-12-23 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method of treating and protecting against central nervous system ischemia, hypoxia, degeneration, and trauma with a 5-aminocarbonyl-sh-dibenzo[a,d]cyclohepten-5,10-imine

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996018391A2 (en) * 1994-12-14 1996-06-20 Lifegroup S.P.A. Use of mono and bicarboxylic acid amides for the manufacture of a medicament active at the peripheral cannabinoid receptor
WO1996018391A3 (en) * 1994-12-14 1996-08-15 Lifegroup Spa Use of mono and bicarboxylic acid amides for the manufacture of a medicament active at the peripheral cannabinoid receptor
WO2002094302A1 (en) * 2001-05-23 2002-11-28 Gil-Ja Jhon Compositions comprising extract of ganoderma lucidum, oleamide and its structural analogue as an effective component for preventing or treating dementia

Also Published As

Publication number Publication date
ITMI940523A0 (it) 1994-03-21
IT1271623B (it) 1997-06-04
ATE182075T1 (de) 1999-07-15
JPH09510467A (ja) 1997-10-21
EP0804179B1 (en) 1999-07-14
WO1995025509A3 (en) 1995-10-12
DE69510825D1 (de) 1999-08-19
EP0804179A2 (en) 1997-11-05
ITMI940523A1 (it) 1995-09-21
US5925678A (en) 1999-07-20
AU2109095A (en) 1995-10-09

Similar Documents

Publication Publication Date Title
EP0799188B1 (en) Amides of mono and dicarboxylic acids with glycosamines, selectively active on the cannabinoid peripheral receptor
US5506224A (en) N-acyl derivatives of aminoalcohols active as local autacoids and useful in the therapy of autoimmune processes
JP4216330B2 (ja) 末梢カンナビノイドレセプターで作用する薬物製造でのモノおよびビカルボン酸アミドの利用
JP5932830B2 (ja) 炎症及び疼痛を処置するための３‐メタンスルホニルプロピオニトリル
CA2086442A1 (en) N-acyl derivatives of aminoalcohols active as local autocoidis and useful in the therapy of autoimmune processes
JPH0144170B2 (und)
CN1974545B (zh) 长链脂肪酰胺类化合物及其应用
EP0804179B1 (en) Use of n-acyl derivatives of aminoalcohols in the manufacture of a medicament for practising neuroprotective action in neuropathological states connected with excitotoxicity
JPH05339153A (ja) アミノアルコールとポリカルボン酸とのｎ−アシル誘導体を含む医薬組成物
EP1592418B1 (en) Use of endocannabinoid-like compounds for treating cns degenerative disorders
JP4063864B2 (ja) 興奮性毒性に関連した中枢神経系の急性ならびに慢性障害に有用な、神経保護、神経栄養、ならびに抗炎症作用を有するｎ−アシルアルキルアミンのグルコシド誘導体
CN103384522B (zh) 咖啡酸衍生物和它们在改善神经细胞生存力中的用途
CA2186243C (en) Use of n-acyl derivatives of aminoalcohols in the manufacture of a medicament for practising neuroprotective action in neuropathological states connected with excitotoxicity
AU2017262155A1 (en) Certain protein kinase inhibitors
WO2013064714A1 (es) Fármacos inhibidores de p38 y aplicaciones
JP6360163B2 (ja) ３，４−ビス−ベンジルスルホニルブタンニトリル及びその医薬上の使用
JP6426746B2 (ja) ４−メチルスルホニル−２−ブテンニトリル及びその医薬上の使用
CA2186245C (en) Glucosidic derivatives of n-acyl alkylamines exerting neuroprotective, neurotrophic and anti-inflammatory action, useful in acute and chronic disorders of the central nervous system connected with excitotoxicity
TW541295B (en) A novel substituted alkylteraamine derivative for use as tachykinin antagonist
EP0504180B1 (en) Glycyl-p-amino-pyridine for the treatment of senile dementia states
KR100188799B1 (ko) 뇌성 말라리아 치료용 카스타노스페르민 에스테르
JPS6048987A (ja) ピラジンカルボン酸誘導体およびその製造法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AU BB BG BR BY CA CN CZ EE FI GE HU JP KE KG KP KR KZ LK LR LT LV MD MG MN MW MX NO NZ PL RO RU SD SG SI SK TJ TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AM AU BB BG BR BY CA CN CZ EE FI GE HU JP KE KG KP KR KZ LK LR LT LV MD MG MN MW MX NO NZ PL RO RU SD SG SI SK TJ TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2186243

Country of ref document: CA

Ref document number: 08714113

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1995928865

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1995928865

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1995928865

Country of ref document: EP